Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
France
/
Materials
/
Arkema
Create a narrative
Arkema Community
ENXTPA:AKE Community
3
Narratives
written by author
0
Comments
on narratives written by author
43
Fair Values set
on narratives written by author
Community Investing Ideas
Arkema
Popular
Undervalued
Overvalued
Arkema
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Urbanization And Sustainability Will Drive Specialty Materials Demand
Key Takeaways Strategic focus on specialty materials and rapid innovation enables sustainable, high-margin growth across advanced technology sectors, reducing vulnerability to commodity cycles. Structural cost savings and disciplined capital allocation drive stronger free cash flow, supporting greater shareholder returns through dividends, buybacks, and targeted acquisitions.
View narrative
€95
FV
38.7% undervalued
intrinsic discount
3.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
7 days ago
author updated this narrative
Arkema
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
New Capacity And R&D Focus Will Accelerate Renewable Transition
Key Takeaways Strategic investments in production and innovation strengthen Arkema's position in specialty materials, enabling growth in eco-friendly markets like renewables and advanced electronics. Emphasis on cost efficiency, strong cash generation, and geographic diversification enhances financial resilience and supports ongoing growth initiatives and shareholder value.
View narrative
€77.06
FV
24.4% undervalued
intrinsic discount
2.88%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
25
users have followed this narrative
14 days ago
author updated this narrative
Arkema
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Asian Overcapacity And Regulatory Hurdles Will Erode Profitability
Key Takeaways Global overcapacity and regulatory changes threaten Arkema's margins and long-term profitability, especially in traditional and commodity chemical segments. Execution risks from slow portfolio transition and external market pressures could limit growth in specialty materials and overall earnings stability.
View narrative
€56
FV
4.0% overvalued
intrinsic discount
0.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
28 days ago
author updated this narrative